Low Serum 1,5-Anhydroglucitol Levels Linked to Increased Mortality Risk in Type 2 Diabetes

Strategic Insights -

Researchers from the Institute of Health in Shanghai, People's Republic of China, have conducted a real-world cohort study to examine the correlation between serum 1,5-anhydroglucitol (1,5-AG) levels and the risk of all-cause and cardiovascular mortality in type 2 diabetes patients. The study, published in Diabetes, Obesity and Metabolism, found that lower serum 1,5-AG levels were significantly linked to an elevated risk of all-cause and cardiovascular mortality in type 2 diabetes. This research has significant implications for the management and treatment of type 2 diabetes, highlighting the importance of monitoring serum 1,5-AG levels over 1-2 weeks to assess glycemic control and postprandial hyperglycemia.

Key Takeaways:

  • The study involved a real-world cohort of 3721 patients with type 2 diabetes, who were classified by 1,5-AG levels.
  • Lower serum 1,5-AG levels were significantly associated with an increased risk of all-cause and cardiovascular mortality in type 2 diabetes patients.
  • The study suggests that monitoring serum 1,5-AG levels over 1-2 weeks can be a useful tool for assessing glycemic control and postprandial hyperglycemia in type 2 diabetes patients.
  • The results of this study have significant implications for the management and treatment of type 2 diabetes, highlighting the importance of considering serum 1,5-AG levels when making treatment decisions.
  • The study's findings emphasize the need for early detection and intervention to prevent long-term complications associated with type 2 diabetes.
  • The research team, led by Lei Chen, consists of experts from the Institute of Health Information, Shanghai Municipal Center for Disease Control and Prevention, and other reputable academic institutions.
  • The study's findings are consistent with previous research on the predictive value of serum 1,5-AG levels for long-term outcomes in type 2 diabetes.

Statistics:

  • 3721 patients with type 2 diabetes were involved in the real-world cohort study.
  • The study found that lower serum 1,5-AG levels were significantly linked to an elevated risk of all-cause and cardiovascular mortality in type 2 diabetes.
  • The risk of all-cause mortality was 19.3% higher in patients with low 1,5-AG levels compared to those with high 1,5-AG levels.
  • The risk of cardiovascular mortality was 25.1% higher in patients with low 1,5-AG levels compared to those with high 1,5-AG levels.
  • The study's findings suggest that monitoring serum 1,5-AG levels over 1-2 weeks can be a useful tool for assessing glycemic control and postprandial hyperglycemia in type 2 diabetes patients.

Sources:

  • Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study. Diabetes, Obesity and Metabolism, 2025.
  • NewsRx. Researchers from Institute of Health Discuss Findings in Type 2 Diabetes (Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study). Cardiovascular Week. October 27, 2025; p 562.